212 related articles for article (PubMed ID: 25763109)
1. Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour.
Charlton J; Williams RD; Sebire NJ; Popov S; Vujanic G; Chagtai T; Alcaide-German M; Morris T; Butcher LM; Guilhamon P; Beck S; Pritchard-Jones K
Genome Med; 2015; 7(1):11. PubMed ID: 25763109
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors.
Chilukamarri L; Hancock AL; Malik S; Zabkiewicz J; Baker JA; Greenhough A; Dallosso AR; Huang TH; Royer-Pokora B; Brown KW; Malik K
Neoplasia; 2007 Nov; 9(11):970-8. PubMed ID: 18030365
[TBL] [Abstract][Full Text] [Related]
3. Proliferation and maturation indices in nephrogenic rests and Wilms tumor; the emergence of heterogeneity from dormant nodular renal blastema.
Bove KE; Lewis C; Debrosse BK
Pediatr Pathol Lab Med; 1995; 15(2):223-44. PubMed ID: 8597811
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney.
Yun K; Molenaar AJ; Fiedler AM; Mark AJ; Eccles MR; Becroft DM; Reeve AE
Lab Invest; 1993 Nov; 69(5):603-15. PubMed ID: 7504120
[TBL] [Abstract][Full Text] [Related]
5. Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting.
Dao D; Walsh CP; Yuan L; Gorelov D; Feng L; Hensle T; Nisen P; Yamashiro DJ; Bestor TH; Tycko B
Hum Mol Genet; 1999 Jul; 8(7):1337-52. PubMed ID: 10369881
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience.
Vujanić GM; Apps JR; Moroz V; Ceroni F; Williams RD; Sebire NJ; Pritchard-Jones K
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383760
[TBL] [Abstract][Full Text] [Related]
7. The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor.
Legge D; Li L; Moriarty W; Lee D; Szemes M; Zahed A; Panousopoulos L; Chung WY; Aghabi Y; Barratt J; Williams R; Pritchard-Jones K; Malik KTA; Oltean S; Brown KW
Mol Oncol; 2022 Feb; 16(3):630-647. PubMed ID: 34520622
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors.
Chung WY; Yuan L; Feng L; Hensle T; Tycko B
Hum Mol Genet; 1996 Aug; 5(8):1101-8. PubMed ID: 8842727
[TBL] [Abstract][Full Text] [Related]
9. Teratoma-associated and so-called pure Wilms tumour of the ovary represent two separate tumour types with distinct molecular features.
Kommoss FKF; Chong AS; Apellaniz-Ruiz M; Turashvili G; Park KJ; Hanley K; Valera ET; von Deimling A; Vujanic G; McCluggage WG; Foulkes WD
Histopathology; 2024 Mar; 84(4):683-696. PubMed ID: 38084641
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic lesions at the H19 locus in Wilms' tumour patients.
Moulton T; Crenshaw T; Hao Y; Moosikasuwan J; Lin N; Dembitzer F; Hensle T; Weiss L; McMorrow L; Loew T; Kraus W; Gerald W; Tycko B
Nat Genet; 1994 Jul; 7(3):440-7. PubMed ID: 7920666
[TBL] [Abstract][Full Text] [Related]
11. Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression.
Guerra JVDS; Pereira BMS; Cruz JGVD; Scherer NM; Furtado C; Montalvão de Azevedo R; Oliveira PSL; Faria P; Boroni M; de Camargo B; Maschietto M
Cells; 2019 Aug; 8(8):. PubMed ID: 31426508
[TBL] [Abstract][Full Text] [Related]
12. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities.
Haruta M; Arai Y; Sugawara W; Watanabe N; Honda S; Ohshima J; Soejima H; Nakadate H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Genes Chromosomes Cancer; 2008 Aug; 47(8):712-27. PubMed ID: 18464243
[TBL] [Abstract][Full Text] [Related]
13. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor.
Beckwith JB; Kiviat NB; Bonadio JF
Pediatr Pathol; 1990; 10(1-2):1-36. PubMed ID: 2156243
[TBL] [Abstract][Full Text] [Related]
15. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor.
Malik K; Salpekar A; Hancock A; Moorwood K; Jackson S; Charles A; Brown KW
Cancer Res; 2000 May; 60(9):2356-60. PubMed ID: 10811108
[TBL] [Abstract][Full Text] [Related]
16. Bilateral Wilms tumour: a review of clinical and molecular features.
Charlton J; Irtan S; Bergeron C; Pritchard-Jones K
Expert Rev Mol Med; 2017 Jul; 19():e8. PubMed ID: 28716159
[TBL] [Abstract][Full Text] [Related]
17. Angiogenin expression in human kidneys and Wilms' tumours: relationship with hypoxia and angiogenic factors.
Ramani P; Headford A; Sowa-Avugrah E; Hunt LP
Int J Exp Pathol; 2013 Apr; 94(2):115-25. PubMed ID: 23419171
[TBL] [Abstract][Full Text] [Related]
18. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.
Hancock AL; Brown KW; Moorwood K; Moon H; Holmgren C; Mardikar SH; Dallosso AR; Klenova E; Loukinov D; Ohlsson R; Lobanenkov VV; Malik K
Hum Mol Genet; 2007 Feb; 16(3):343-54. PubMed ID: 17210670
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of carbonic anhydrase and HIF-1α in Wilms tumours.
Dungwa JV; Hunt LP; Ramani P
BMC Cancer; 2011 Sep; 11():390. PubMed ID: 21910893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
